Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
By Deena Beasley LOS ANGELES (Reuters) - Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG , new data shows, helping explain why sales of the two products have not met rosy expectations.
The post Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments appeared first on Firstpost.
from Firstpost https://ift.tt/2KfvIXi
via IFTTT